register

News & Trends - Pharmaceuticals

No-deal Brexit could disrupt medicine supplies for up to six months

Health Industry Hub | September 23, 2019 |

The UK government on Wednesday published a document explaining how a no-deal Brexit beginning on 31 October could strain trade across the English Channel for up to six months.

“The reliance of medicines and medical products’ supply chains on the short straits crossing make them particularly vulnerable to severe extended delays; three-quarters of medicines come via the short straits,” the document says.

The document explains how medicine and medical supply chains are highly regulated and require transportation that meets strict Good Distribution Practices.

“This can include limits on time of transit, or mean product must be transported under temperature-controlled conditions. Whilst some products can be stockpiled, others cannot due to short shelf lives – it will also not be practical to stockpile products to cover expected delays of up to six months.”

The UK’s Department of Health and Social Care (DHSC) said it is developing a “multi-layered approach” to mitigate these risks. DHSC also previously established a £25 million contract to set up a 12-month express freight service to deliver medicines and medical products into the country.

Sheuli Porkess, director of research, medical and innovation at the Association of the British Pharmaceutical Industry, said in a statement: “Government measures have supported these preparations. Companies now need the practical detail on how some of these measures, like additional freight capacity, will work in practice.”

The UK’s Medicines and Healthcare products Regulatory Agency has published a series of no-deal Brexit guidance documents to help with such a transition.

We’re seeking your input. Share your views in 2 short minutes to help the Pharma, MedTech and Biotech industry professionals.

With more than 80% of healthcare and pharma organisations doing more with fewer resources (recent PwC report), how is superior value being delivered by the external service providers and suppliers you work with regularly to support you in your role in Pharma, Biotech or MedTech? Which gaps can be addressed to better assist you? Share your opinion in 2 short minutes.


News & Trends - Pharmaceuticals

Federal Health Minister succumbs to pressure, commits to extra meeting to clear PBAC backlog

Federal Health Minister succumbs to pressure, commits to extra meeting to clear PBAC backlog

Health Industry Hub | November 7, 2024 |

Pharma News: The Minister for Health and Aged Care, Mark Butler MP, has confirmed that the Pharmaceutical Benefits Advisory Committee […]

More


News & Trends - MedTech & Diagnostics

Medtech company partners with Aussie researchers in AI technology for GI cancer detection

Medtech company partners with Aussie researchers in AI technology for GI cancer detection

Health Industry Hub | November 7, 2024 |

MedTech & Diagnostics News: To develop a next-generation gastrointestinal (GI) flexible endomicroscope equipped with edge-artificial intelligence (AI) technology, Monash University’s […]

More


News & Trends - Pharmaceuticals

Local oncologists first to enrol prostate cancer patients in phase 3 theranostics trial

Local oncologists first to enrol prostate cancer patients in phase 3 theranostics trial

Health Industry Hub | November 7, 2024 |

Pharma News: GenesisCare oncologists have achieved a significant milestone, becoming the first to enrol and deliver patient treatment in a […]

More


Human Resources

Ipsen's culture of 'collaboration and diversity' earns Great Place to Work certification

Ipsen’s culture of ‘collaboration and diversity’ earns Great Place to Work certification

Health Industry Hub | November 6, 2024 |

Ipsen Australia and New Zealand has announced its certification as a Great Place to Work in 2024, joining 11 other […]

More


This content is copyright protected. Please subscribe to gain access.